Arena Pharma: FDA Approval of First Weight-Loss Drug in 13 Years $ARNA

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) engages in the clinical development of biotechnology products, primarily focused on the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.  Arena has generated massive buzz as of late with the much-publicized FDA approval of obesity drug lorcaserin (Belviq).  While the results of clinical trials have demonstrated a modest 5% reduction in weight compared to placebo controls, the continued obesity epidemic in the United States has created a massive consumer base that is actively looking for an answer.  While this answer may be Belviq, it will need stronger data before the drug receives backing from insurers. With an estimated 42 percent of the U.S. population facing obesity by 2030, the announcement of Belviq’s FDA approval helped catalyze an intraday appreciation of as much as 53 percent during Wednesday last week, only to be followed by a 10% cool down the following day.  Nevertheless, Arena’s move to commercialize this potentially lucrative product has undoubtedly gained the attention of competitors Vivus (VVUS) and Orexigen Therapeutics (OREX).

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

At the end of the 1st quarter of this financial year, there were a total of 9 hedge funds invested in Arena Pharmaceutials, with a modest net investment of $13.8 million of its $1.87 billion total market capitalization.  This compares to $597.8 million of hedge fund activity within Vivus ($2.84 billion market cap) and $38.2 million of capital invested in Orexigen ($399.88 million market cap).  The holders of Arena’s stock includes Daniel GoldDE ShawIsrael Englander, Glenn Russell Dubin and quant guru Jim Simons, among others.  While the FDA’s approval is a positive sign for ARNA’s strategy going forward, this endorsement may have already been priced into the market, as the stock has risen over 450% in the last three months.  How the company translates the government’s authorization into a commercial success is yet to be seen.  In 2010, Arena made a deal with Japan’s Eisai company for Belviq. Arena will receive an upfront payment of $50 million from Japan’s Eisai company and up to another $90 million in milestone payments for U.S. approval and delivery of the product for sale. Also under agreement, Arena will receive 31.5% on the net sale from Eisai and 36.5% on the portion that exceeds $ 750 million.  As Arena reported a first quarter loss of $ 29.4 million and has 4 drugs in the first stage of development, the regulatory success of Belviq was of critical importance to the future of Arena Pharmaceuticals.

Last week witnessed another regulatory development with regard to the passage of President Obama’s Affordable Care Act.  The Supreme Court’s decision to uphold the highly controversial individual mandate and the legislation’s collective components are expected to have a negligible impact on the pharmaceutical industry.  S&P Equity Research has projected a 2%-3% increase in revenues stemming from extending health insurance coverage to 32 million presently uninsured Americans, which would roughly offset the already-agreed-to Medicare Part D price discounts, higher Medicaid rebates, and new fees.

Belviq’s FDA approval has also led to positive sentiment surrounding VVUS and OREX shares, as the likelihood that their weight loss drugs Qnexa and Contrave, respectively, will be approved has increased as well.  OREX has seen an appreciation of over 70% in the last 30 days, and VVUS stock has appreciated nearly 10% in the last 5 days.  The negative earnings of these three companies are reflected in their negative PEG ratios; ARNA at -1.14, VVUS at -1.63, and OREX at -0.34 over a 5 year projected horizon.  ARNA has a gross margin of 0.41 compared to -2.80 for OREX, which reflects that ARNA is retaining more on each dollar of sales relative to servicing its other costs and obligations.  Free cash flow yields for ARNA, OREX, and VVUS are -4.30%, -6.26% and -1.57% respectively.  Five-year growth projections for ARNA are at 25%, and should be looked at cautiously given the anticipated passage of weight loss drugs from its competitors.  In addition, ARNA has displayed a strong degree of positive correlation with the ‘VIX’ index over the last 60 days, indicating that the stock has generally outperformed the market when uncertainty has spiked.  The potential market size of obesity drugs is extraordinary, with only a 1.2% penetration of the market producing a possible $1.8 billion dollars in US sales by 2018.  Nonetheless, the sheer dependency that large pharmaceutical companies have on a core portfolio of drugs, and in this case, a single drug, makes us hesitant to commit fully to Arena Pharmaceuticals.  Assuming an earnings per share of $0.79 in 2017, and discounted at a 20% growth rate with a Price-to Earnings multiple of 25, the intrinsic value of ARNA is approximately $10/share. Given the recent rally among ARNA and its competitors, one would be wise to wait until further clinical trials have reinforced the efficacy of this potentially blockbuster drug. Until then, the landscape of this industry makes Arena’s Belviq product highly vulnerable to competition.

Note: This article is written by Mohsen Ghazi.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

The 10 Biggest Tax Havens in the World to Stash Your Money

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!